title: Type 1 diabetes: Syndromes in resource-challenged settings.
abstract: Type 1 Diabetes is a complex disorder that is made more complex by the myriad of co-morbid conditions associated with it. Mauriac Syndrome is a well-known but nowadays uncommon condition that presents with growth retardation secondary to poor glycaemic control. Limited Joint Mobility is an often-missed association of diabetes. Its importance lies in the fact that it can cause significant impairment of fine movements in T1DM children. It also indicates poor glycaemic control over a long period of time and can be used as a surrogate marker for development of diabetic microvascular complications. Anaemia in T1DM is protean and can develop due to a combination of nutritional factors, chronic renal disease, coeliac disease and worm infestation. Management is etiological. Vitamin deficiencies are ubiquitous in T1DM and if left untreated, can lead to neurological, haematological and skeletal dysfunction. The best-known co-morbid conditions are the local site reactions clubbed together under the moniker lipodystrophies. These can be either atrophic or hypertrophic and are usually due to repeated injections at the same site, improper technique and needle re-use. Management is often difficult and they are best prevented by appropriate diabetes education and emphasis on proper injection techniques at the time of T1DM diagnosis, with periodic reinforcement. Amyloidosis is a little known condition that shares a lot of features in common with the lipodystrophies and often needs to be differentiated from lipohypertrophy. T1DM is a disease which is often associated with a poor quality of life and these co-morbid conditions also need to be treated for effective general and psychological well-being.
authors.affiliation: Department of Endocrinology, CARE Hospital, Hyderabad, India.
authors.forename: V Sri
authors.initials: VS
authors.lastname: Nagesh
authors.affiliation: Department of Endocrinology, BRIDE Hospital, Karnal, India.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kalra
mesh_terms: D000686:Amyloidosis / Q000209:etiology* / Q000628:therapy; D000740:Anemia / Q000209:etiology* / Q000628:therapy; D001361:Avitaminosis / Q000209:etiology* / Q000628:therapy; D002446:Celiac Disease / Q000150:complications / Q000628:therapy; D048909:Diabetes Complications / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D003922:Diabetes Mellitus, Type 1 / Q000150:complications* / Q000188:drug therapy; D019468:Disease Management; D006130:Growth Disorders / Q000209:etiology* / Q000628:therapy; D006295:Health Resources; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007279:Injections, Subcutaneous / Q000009:adverse effects; D007328:Insulin / Q000627:therapeutic use; D007592:Joint Diseases / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D008060:Lipodystrophy / Q000209:etiology* / Q000628:therapy; D016059:Range of Motion, Articular; D013577:Syndrome
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin
keywords: Type 1 diabetes, Mauriac, Limited Joint Mobility, Lipodystrophy, Lipoatrophy, Anaemia, Lipohypertrophy, Amyloidosis, Brink-Starkman.